- Home
- VTAK vs TOVX Comparison
VTAK vs TOVX Comparison
Compare VTAK & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTAK
- TOVX
- Stock Information
- Founded
- VTAK 2002
- TOVX 2001
- Country
- VTAK United States
- TOVX United States
- Employees
- VTAK N/A
- TOVX N/A
- Industry
- VTAK Medical/Dental Instruments
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- VTAK Health Care
- TOVX Health Care
- Exchange
- VTAK Nasdaq
- TOVX Nasdaq
- Market Cap
- VTAK 4.1M
- TOVX 3.8M
- IPO Year
- VTAK 2018
- TOVX 2006
- Fundamental
- Price
- VTAK $2.72
- TOVX $0.30
- Analyst Decision
- VTAK
- TOVX Hold
- Analyst Count
- VTAK 0
- TOVX 1
- Target Price
- VTAK N/A
- TOVX N/A
- AVG Volume (30 Days)
- VTAK 417.2K
- TOVX 13.9M
- Earning Date
- VTAK 11-12-2025
- TOVX 11-11-2025
- Dividend Yield
- VTAK N/A
- TOVX N/A
- EPS Growth
- VTAK N/A
- TOVX N/A
- EPS
- VTAK N/A
- TOVX N/A
- Revenue
- VTAK $600,000.00
- TOVX N/A
- Revenue This Year
- VTAK $822.86
- TOVX N/A
- Revenue Next Year
- VTAK $168.42
- TOVX N/A
- P/E Ratio
- VTAK N/A
- TOVX N/A
- Revenue Growth
- VTAK 37.62
- TOVX N/A
- 52 Week Low
- VTAK $2.20
- TOVX $0.29
- 52 Week High
- VTAK $20.14
- TOVX $2.64
- Technical
- Relative Strength Index (RSI)
- VTAK 55.54
- TOVX 42.24
- Support Level
- VTAK $2.52
- TOVX $0.39
- Resistance Level
- VTAK $2.83
- TOVX $0.86
- Average True Range (ATR)
- VTAK 0.22
- TOVX 0.08
- MACD
- VTAK -0.01
- TOVX -0.01
- Stochastic Oscillator
- VTAK 28.99
- TOVX 2.75
About VTAK Catheter Precision Inc.
Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.